Show simple item record

dc.contributor.authorTyler, R
dc.contributor.authorDavies, E
dc.contributor.authorTan, D
dc.contributor.authorHodson, J
dc.contributor.authorTaniere, P
dc.contributor.authorThway, K
dc.contributor.authorJafri, M
dc.contributor.authorAlmond, M
dc.contributor.authorFord, S
dc.contributor.authorStrauss, D
dc.contributor.authorHayes, A
dc.contributor.authorSmith, M
dc.contributor.authorDesai, A
dc.date.accessioned2020-11-23T13:12:56Z
dc.date.issued2020-11-10
dc.identifier.citationJournal of surgical oncology, 2020
dc.identifier.issn0022-4790
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4239
dc.identifier.eissn1096-9098
dc.identifier.doi10.1002/jso.26294
dc.description.abstractBackground objectives The impact of tumor necrosis as a prognostic factor in gastrointestinal stromal tumor (GISTs) is still debated. The objective was to determine whether tumor necrosis is an independent risk factor for survival in patients with GISTs.Methods Patients undergoing surgery for primary GIST from March 2003 to October 2018 at two sarcoma referral centers were retrospectively identified. Patients who received neoadjuvant imatinib were excluded. Multivariable Cox regression models were produced, to assess whether tumor necrosis was an independent predictor of either overall or recurrence-free survival.Results Forty-one out of 195 (21.0%) patients had tumor necrosis. Tumor necrosis was associated with a significantly higher modified National Institute of Health risk score, with 29 out of 41 (70.7%) patients with necrosis classified as high risk, compared to 52 out of 153 (34.0%) without (p < .001). Tumor necrosis was found to be independently predictive of recurrence-free survival (hazard ratio: 5.26, 95% CI: 2.62-10.56, p < .001) on multivariable analysis. At 5 years, 44.3% of patients with necrosis had either died or developed recurrence, compared to 9.9% of those without.Conclusion Tumor necrosis is an independent predictor of recurrence-free survival in patients with operable GISTs. It should be routinely reported by pathologists, and used by clinicians when counseling patients and deciding on adjuvant therapy.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleTumor necrosis is significantly associated with reduced recurrence-free survival after curative resection of gastrointestinal stromal tumors.
dc.typeJournal Article
dcterms.dateAccepted2020-10-30
rioxxterms.versionofrecord10.1002/jso.26294
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-11-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of surgical oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamSarcoma and Melanoma Surgeryen_US
dc.contributor.icrauthorSmith, Mylesen
dc.contributor.icrauthorHayes, Andrewen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record